Page 25 - 09 EMA

ndication

hildren and adolescents agedsix to 17years, who have had an
nadequate response to conventional therapy including corticosteroids
and 6MP or AZA, or who are intolerant to or have medical
ontraindications for such therapies.
Ankylosing spondylitis
Remsimais indicated for treatment of severe, active ankylosing
pondylitis, in adult patients who have responded inadequately to
onventional therapy.
Psoriatic arthritis
Remsimais indicated for treatment of active and progressive psoriatic
arthritis in adult patients when the response to previous DMARD
herapy has been inadequate.
Remsima should be administered:

 in combination with methotrexate;
 or alone in patients who show intolerance to methotrexate or for

whom methotrexate is contraindicated.
nfliximab has been shown to improve physical function in patients with
psoriatic arthritis, and to reduce the rate of progression of peripheral
oint damage as measured by Xray in patients with polyarticular
ymmetrical subtypes of the disease.
Psoriasis
Remsimais indicated for treatment of moderate to severe plaque
psoriasis in adult patients who failed to respond to, or who have a
ontraindication to, or are intolerant to other systemic therapy including
yclosporine, methotrexate or psoralen ultra-violet A (PUVA).
Treatment of symptomatic anaemia associated with chronic renal failure
CRF) in adult and paediatric patients:

 treatment of anaemia associated with chronic renal failure in
adult and paediatric patients on haemodialysis and adult
patients on peritoneal dialysis;

 treatment of severe anaemia of renal origin accompanied by

- 13 -